1887

Chapter 16 : Treatment of Experimental and Human Bacterial Endocarditis with Quinolone Antimicrobial Agents

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Ebook: Choose a downloadable PDF or ePub file. Chapter is a downloadable PDF file. File must be downloaded within 48 hours of purchase

Buy this Chapter
Digital (?) $15.00

Preview this chapter:
Zoom in
Zoomout

Treatment of Experimental and Human Bacterial Endocarditis with Quinolone Antimicrobial Agents, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555817817/9781555812317_Chap16-1.gif /docserver/preview/fulltext/10.1128/9781555817817/9781555812317_Chap16-2.gif

Abstract:

Effective antimicrobial agents must sterilize vegetations containing high bacterial densities in the presence of an indwelling foreign body. This chapter concentrates predominantly on a detailed analysis of the results of quinolone treatment protocols in discriminative animal models of bacterial endocarditis (BE) that may be relevant to the treatment of human BE. In addition, the available literature on the efficacy of quinolones in human BE is summarized. This therapeutic difference occurred despite the β-lactam agents being present within infected vegetations at concentrations above the minimal bactericidal concentrations (MBCs) for periods similar to those observed in the ciprofloxacin-treated animals. This study confirmed the importance of pharmacodynamic parameters such as postantibiotic effect and time-above-MBC at the tissue infection site as dual determinants of the outcome of β-lactam therapy in experimental BE. The Dworkin and coworkers study was an open, nonrandomized evaluation, and the excellent results prompted a larger, prospective, randomized trial comparing oral ciprofloxacin plus rifampin versus nafcillin plus gentamicin in addict-related, right-sided BE. The newer quinolones (e.g., levofloxacin and trovafloxacin) also appear to be highly active in vivo against both methicillin-susceptible (MSSA) and methicillin-resistant (MRSA) strains in experimental BE models.

Citation: Le T, Yeaman M, Bayer A. 2003. Treatment of Experimental and Human Bacterial Endocarditis with Quinolone Antimicrobial Agents, p 259-273. In Hooper D, Rubinstein E (ed), Quinolone Antimicrobial Agents, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555817817.ch16
Highlighted Text: Show | Hide
Loading full text...

Full text loading...

References

/content/book/10.1128/9781555817817.chap16
1. Auckenthaler, R.,, M. Michea-Hamzehpour,, and J . C. Pechere. 1986. In-vitro activity of newer quinolones against aerobic bacteria. J. Antimicrob. Chemother. 17(Suppl. B):2939.
2. Babinchak, T. J. 1995. Oral ciprofloxacin therapy for prosthetic valve endocarditis due to Actinobacillus actinomycetemcomitans. Clin. Infect. Dis. 21:15171518.
3. Baca, O. G.,, and D. Paretsky. 1983. Q fever and Coxiella burnetii: a model for host-parasite interactions. Microbiol. Rev. 47:127149.
4. Bauernfeind, A.,, and C. Petermuller. 1983. In vitro activity of ciprofloxacin, norfloxacin and nalidixic acid. Eur. J. Clin. Microbiol. 2:111115.
5. Bayer, A. S.,, I. K. Blomquist,, and K. S. Kim. 1986. Ciprofloxacin in experimental aortic valve endocarditis due to Pseudomonas aeruginosa. J. Antimicrob. Chemother. 17:641649.
6. Bayer, A. S.,, D. P. Greenberg,, and J . Yih. 1988. Correlates of therapeutic efficacy in experimental methicillin-resistant Staphylococcus aureus endocarditis. Chemotherapy 34:4655.
7. Bayer, A. S.,, L. Hirano,, and J . Yih. 1988. Development of beta-lactam resistance and increased quinolone MICs during therapy of experimental Pseudomonas aeruginosa endocarditis. Antimicrob. Agents Chemother. 32:231235.
8. Bayer, A. S., and K. S. Kim. 1986. In vivo efficacy of azlocillin and amikacin versus ciprofloxacin with and without amikacin in experimental right-sided endocarditis due to Pseudomonas aeruginosa. Chemotherapy 32:364373.
9. Bayer, A. S.,, C. Li,, and M. Ing. 1998. Efficacy of trovafloxacin, a new quinolone antibiotic, in experimental staphylococcal endocarditis due to oxacillin-resistant strains. Antimicrob. Agents Chemother. 42:18371841.
10. Bayer, A. S.,, P. Lindsay,, J . Yih,, L. Hirano,, D. Lee,, and I. K. Blomquist. 1986. Efficacy of ciprofloxacin in experimental aortic valve endocarditis caused by a multiply beta-lactamresistant variant of Pseudomonas aeruginosa stably derepressed for beta-lactamase production. Antimicrob. Agents Chemother. 30:528531.
11. Bayer, A. S.,, D. Norman,, and D. Anderson. 1985. Efficacy of ciprofloxacin in experimental arthritis caused by Escherichia coli —in vitro-in vivo correlations. J. Infect. Dis. 152:811816.
12. Bayer, A. S.,, D. Norman,, and K. S. Kim. 1985. Efficacy of amikacin and ceftazidime in experimental aortic valve endocarditis due to Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 28:781785.
13. Bayer, A. S.,, J . Peters,, T. R. Parr, Jr.,, L. Chan,, and R. E. Hancock. 1987. Role of beta-lactamase in in vivo development of ceftazidime resistance in experimental Pseudomonas aeruginosa endocarditis. Antimicrob. Agents Chemother. 31:253258.
14. Berrington, A. W.,, R. J. Koerner,, J. D. Perry,, H. H. Bain,, and F. K. Gould. 2001. Treatment of Staphylococcus aureus endocarditis using moxifloxacin. Int. J. Med. Microbiol. 291:237239.
15. Bignardi, G. E. 1989. Ciprofloxacin resistance and staphylococcal endocarditis. Lancet ii:1526.
16. Boscia, J. A.,, W. D. Kobasa,, and D. Kaye. 1987. Comparison of difloxacin, enoxacin, and cefoperazone for treatment of experimental Enterobacter aerogenes endocarditis. Antimicrob. Agents Chemother. 31:458460.
17. Boscia, J. A.,, W. D. Kobasa,, and D. Kaye. 1985. Enoxacin compared with cefoperazone for the treatment of experimental Enterobacter aerogenes endocarditis. Antimicrob. Agents Chemother. 27:708711.
18. Bouza, E.,, M. Garcia de la Torre,, A. Erice,, E. Loza,, J. M. Diaz-Borrego,, and L. Buzon. 1985. Enterobacter bacteremia. An analysis of 50 episodes. Arch. Intern. Med. 145:10241027.
19. Brion, N.,, A. Lessana,, F. Mosset,, J. J. Lefevre,, and G. Montay. 1986. Penetration of pefloxacin in human heart valves. J. Antimicrob. Chemother. 17(Suppl. B):8992.
20. Bugnon, D.,, G. Potel,, Y.Q. Xiong,, J . Caillon,, D. Navas,, C. Gras,, M. F. Kergueris,, P. Le Conte,, F. Jehl,, D. Baron,, and H. Drugeon. 1997. Bactericidal effect of pefloxacin and fosfomycin against Pseudomonas aeruginosa in a rabbit endocarditis model with pharmacokinetics of pefloxacin in humans simulated in vivo. Eur. J. Clin. Microbiol. Infect. Dis. 16:575580.
21. Carbon, C. 1990. Impact of the antibiotic dosage schedule on efficacy in experimental endocarditis. Scand. J. Infect. Dis. Suppl. 74:163172.
22. Carpenter, T. C.,, C. J. Hackbarth,, H. F. Chambers,, and M. A. Sande. 1986. Efficacy of ciprofloxacin for experimental endocarditis caused by methicillin-susceptible or -resistant strains of Staphylococcus aureus. Antimicrob. Agents Chemother. 30:382384.
23. Chamberland, S.,, A. S. Bayer,, T. Schollaardt,, S. A. Wong,, and L. E. Bryan. 1989. Characterization of mechanisms of quinolone resistance in Pseudomonas aeruginosa strains isolated in vitro and in vivo during experimental endocarditis. Antimicrob. Agents Chemother. 33:624634.
24. Chambers, H. F.,, Q. Xiang,, Liu,, L. L. Chow,, and C. Hackbarth. 1999. Efficacy of levofloxacin for experimental aortic-valve endocarditis in rabbits infected with viridans group streptococcus or Staphylococcus aureus. Antimicrob. Agents Chemother. 43:27422746.
25. Contrepois, A.,, C. Daldoss,, B. Pangon,, J . J . Garaud,, M. Kecir,, C. Sarrazin,, J. M. Vallois,, and C. Carbon. 1984. Pefloxacin in rabbits: protein binding, extravascular diffusion, urinary excretion and bactericidal effect in experimental endocarditis. J. Antimicrob. Chemother. 14:5157.
26. Cremieux, A. C.,, A. Saleh-Mghir,, J. M. Vallois,, B. Maziere,, M. Muffat-Joly,, C. Devine,, A. Bouvet,, J. J. Pocidalo,, and C. Carbon. 1992. Efficacy of temafloxacin in experimental Streptococcus adjacens endocarditis and autoradiographic diffusion pattern of 1 4C temafloxacin in cardiac vegetations. Antimicrob. Agents Chemother. 36:22162221.
27. Daikos, G. L.,, S. B. Kathpalia,, V. T. Lolans,, G. G. Jackson,, and E. Fosslien. 1988. Long-term oral ciprofloxacin: experience in the treatment of incurable infective endocarditis. Am. J. Med. 84:786790.
28. Dawson, S. J.,, and L. A. White. 1992. Treatment of Haemophilus aphrophilus endocarditis with ciprofloxacin. J. Infect. 24:317320.
29. Durack, D. T., and P. B. Beeson. 1972. Experimental bacterial endocarditis. II. Survival of a bacteria in endocardial vegetations. Br. J. Exp. Pathol. 53:5053.
30. Dworkin, R. J.,, B. L. Lee,, M. A. Sande,, and H. F. Chambers. 1989. Treatment of right-sided Staphylococcus aureus endocarditis in intravenous drug users with ciprofloxacin and rifampicin. Lancet 2:10711073.
31. Eliopoulos, G. M.,, A. Gardella,, and R. C. Moellering, Jr. 1984. In vitro activity of ciprofloxacin, a new carboxyquinoline antimicrobial agent. Antimicrob. Agents Chemother. 25:331335.
32. Endtz, H. P.,, J. W. Mouton,, J. G. den Hollander,, N. van den Braak,, and H. A. Verbrugh. 1997. Comparative in vitro activities of trovafloxacin (CP-99,219) against 445 Grampositive isolates from patients with endocarditis and those with other bloodstream infections. Antimicrob. Agents Chemother. 41:11461149.
33. Entenza, J . M.,, M. Blatter,, M. P. Glauser,, and P. Moreillon. 1994. Parenteral sparfloxacin compared with ceftriaxone in treatment of experimental endocarditis due to penicillin-susceptible and -resistant streptococci. Antimicrob. Agents Chemother. 38:26832688.
34. Entenza, J. M.,, J . Vouillamoz,, M. P. Glauser,, and P. Moreillon. 1997. Levofloxacin versus ciprofloxacin, flucloxacillin, or vancomycin for treatment of experimental endocarditis due to methicillin-susceptible or -resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 41:16621667.
35. Francioli, P.,, W. Ruch,, and D. Stamboulian. 1995. Treatment of streptococcal endocarditis with a single daily dose of ceftriaxone and netilmicin for 14 days: a prospective multicenter study. Clin. Infect. Dis. 21:14061410.
36. Francioli, P. B. 1993. Ceftriaxone and outpatient treatment of infective endocarditis. Infect. Dis. Clin. N. Am. 7:97115.
37. Freedman, L. R., and J . Valone Jr. 1979. Experimental infective endocarditis. Prog. Cardiovasc. Dis. 22:169180.
38. Gengo, F. M.,, T. W. Mannion,, C. H. Nightingale,, and J. J. Schentag. 1984. Integration of pharmacokinetics and pharmacodynamics of methicillin in curative treatment of experimental endocarditis. J. Antimicrob. Chemother. 14:619631.
39. Gilbert, M.,, J. A. Boscia,, W. D. Kobasa,, and D. Kaye. 1986. Enoxacin compared with vancomycin for the treatment of experimental methicillin-resistant Staphylococcus aureus endocarditis. Antimicrob. Agents Chemother. 29:461463.
40. Gomez-Jimenez, J.,, E. Ribera,, B. Almirante,, O. DelValle,, A. Pahissa,, and J. M. Martinez-Vazquez. 1989. Ciprofloxacin resistance and staphylococcal endocarditis. Lancet ii:15251526.
41. Goerre, S.,, R. Malinverni,, and B. C. Aeschbacher. 1998. Successful conservative treatment of non-typhoid Salmonella endocarditis involving a bioprosthetic valve. Clin. Cardiol. 21:368370.
42. Hackbarth, C.J.,, H. F. Chambers,, F. Stella,, A. M. Shibl,, and M. A. Sande. 1986. Ciprofloxacin in experimental Pseudomonas aeruginosa meningitis in rabbits. J. Antimicrob. Chemother. 18(Suppl. D):6569.
43. Haller, I. 1985. Comprehensive evaluation of ciprofloxacinaminoglycoside combinations against Enterobacteriaceae and Pseudomonas aeruginosa strains. Antimicrob. Agents Chemother. 28:663666.
44. Heldman, A. W.,, T. V. Hartert,, S. C. Ray,, E. G. Daoud,, T. E. Kowalski,, V. J. Pompili,, S. D. Sisson,, W. C. Tidmore,, K. A. vom Eigen,, S. N. Goodman,, P. S. Lietman,, B. G. Petty,, and C. Flexner. 1996. Oral antibiotic treatment of rightsided staphylococcal endocarditis in injection drug users: prospective randomized comparison with parenteral therapy. Am. J. Med. 101:6876.
45. Hooper, D. C.,, J. S. Wolfson,, E. Y. Ng,, and M. N. Swartz. 1987. Mechanisms of action of and resistance to ciprofloxacin. Am. J. Med. 82:1220.
46. Hooper, D. C.,, J. S. Wolfson,, K. S. Souza,, C. Tung,, G. L. McHugh,, and M. N. Swartz. 1986. Genetic and biochemical characterization of norfloxacin resistance in Escherichia coli. Antimicrob. Agents Chemother. 29:639644.
47. Ingerman, M. J.,, P. G. Pitsakis,, A. F. Rosenberg,, and M. E. Levison. 1986. The importance of pharmacodynamics in determining the dosing interval in therapy for experimental pseudomonas endocarditis in the rat. J. Infect. Dis. 153:707714.
48. Jimenez-Lucho, V. E.,, L. D. Saravolatz,, A. A. Medeiros,, and D. Pohlod. 1986. Failure of therapy in pseudomonas endocarditis: selection of resistant mutants. J. Infect. Dis. 154:6468.
49. Kaatz, G. W.,, S. L. Barriere,, D. R. Schaberg,, and R. Fekety. 1987. Ciprofloxacin versus vancomycin in the therapy of experimental methicillin-resistant Staphylococcus aureus endocarditis. Antimicrob. Agents Chemother. 31:527530.
50. Kaatz, G. W.,, S. L. Barriere,, D. R. Schaberg,, and R. Fekety. 1987. The emergence of resistance to ciprofloxacin during treatment of experimental Staphylococcus aureus endocarditis. J. Antimicrob. Chemother. 20:753758.
51. Kaatz, G. W.,, S. M. Seo,, J. R. Aeschlimann,, H. H. Houlihan,, R. C. Mercier,, and M. J. Rybak. 1998. Efficacy of trovafloxacin against experimental Staphylococcus aureus endocarditis. Antimicrob. Agents Chemother. 42:254256.
52. Kaatz, G. W.,, S. M. Seo,, S. L. Barriere,, L. M. Albrecht,, and M. J . Rybak. 1991. Development of resistance to fleroxacin during therapy of experimental methicillin-susceptible Staphylococcus aureus endocarditis. Antimicrob. Agents Chemother. 35:15471550.
53. Kaatz, G. W.,, S. M. Seo,, and C. A. Ruble. 1991. Mechanisms of fluoroquinolone resistance in Staphylococcus aureus. J. Infect. Dis. 163:10801086.
54. Kamoun, S.,, A. Hammami,, S. Ben Hamed,, M. M. Sahnoun,, F. Elleuch,, and M. Daoud. 1991. Brucella endocarditis on Starr aortic valve prosthesis. Arch. Mai. Coeur Vaiss 84:269271.
55. Karchmer, A. W. 1985. Staphylococcal endocarditis. Laboratory and clinical basis for antibiotic therapy. Am. J. Med. 78:116127.
56. Katsarolis, I.,, A. Pefanis,, D. Hiopoulos,, P. Siaperas,, P. Karayiannakos,, and H. Giamarellou. 2000. Successful trovafloxacin prophylaxis against experimental streptococcal aortic valve endocarditis. Antimicrob. Agents Chemother. 44:25642566.
57. Kim, Y. S.,, Q. Liu,, L. L. Chow,, H. F. Chambers,, and M. G. Tauber. 1998. Comparative efficacy of trovafloxacin in experimental endocarditis caused by ciprofloxacin-sensitive, methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 42:33253327.
58. Kupferwasser, L. I.,, and A. S. Bayer. 2001. Efficacy of a new des-F(6) quinolone, BMS-284756, in the rabbit model of experimental right-sided endocarditis and lung abscess due to a microaerophilic Streptococcus, abstr. B-788 Program and Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
59. Landman, D.,, J . M. Quale,, N. Mobarakai,, and M. M. Zaman. 1995. Ampicillin plus ciprofloxacin therapy of experimental endocarditis caused by multidrug-resistant Enterococcus faecium. J. Antimicrob. Chemother. 36:253258.
59a. Lepidi, H.,, P. Houpikian,, Z. Liang,, and D. Raoult. 2003. Cardiac valves in patients with Q fever with endocarditis: microbiological, molecular, and histologic studies. J. Infect. Dis. 187:10971106.
60. Levy, P. Y.,, M. Drancourt,, J . Etienne,, J. C. Auvergnat,, J . Beytout,, J . M. Sainty,, F. Goldstein,, and D. Raoult. 1991. Comparison of different antibiotic regimens for therapy of 32 cases of Q fever endocarditis. Antimicrob. Agents Chemother. 35:533537.
61. Maurin, M.,, A. M. Benoliel,, P. Bongrand,, and D. Raoult. 1992. Phagolysosomal alkalinization and the bactericidal effect of antibiotics: the Coxiella burnetii paradigm. J. Infect. Dis. 166:10971102.
62. Maserati, R.,, A. E. Cagni,, and C. Segu. 1996. Sparfloxacin therapy for experimental endocarditis caused by methicillinresistant Staphylococcus aureus. Chemotherapy 42:133139.
63. Palmer, S.R.,, and S. E. Young. 1982. Q-fever endocarditis inEngland and Wales, 1975-81. Lancet 2:14481449.
64. Papadakis, J. A.,, G. Samonis,, S. Maraki,, J . Boutsikakis,, V. Petrocheilou,, and G. Saroglou. 2000. Efficacy of amikacin, ofloxacin, pefloxacin, ciprofloxacin, enoxacin, and fleroxacin in experimental left-sided Pseudomonas aeruginosa endocarditis. Chemotherapy 46:116121.
65. Piper, K. E.,, M. S. Rouse,, K. L. Ronningen,, J. M. Steckelberg,, W. R. Wilson,, and R. Patel. 2000. Trovafloxacin treatment of viridans group Streptococcus experimental endocarditis. Antimicrob. Agents Chemother. 44:25542556.
66. Pohlod, D.J.,, L. D. Saravolatz,, and M. M. Somerville. 1988. In-vitrosusceptibility of staphylococci to fleroxacin in comparison with six otherquinolones. J. Antimicrob. Chemother. 22(Suppl. D):3541.
67. Preheim, L. C.,, R. G. Penn,, C. C. Sanders,, R. V. Goering,, and D. K. Giger. 1982. Emergence of resistance to beta-lactam and aminoglycoside antibiotics during moxalactam therapy of Pseudomonas aeruginosa infections. Antimicrob. Agents Chemother. 22:10371041.
68. Quale, J. M.,, D. Landman,, and N. Mobarakai. 1994. Treatment of experimental endocarditis due to multidrug resistant Enterococcus faecium with ciprofloxacin and novobiocin. J. Antimicrob. Chemother. 34:797802.
69. Raoult, D.,, P. Bres,, M. Drancourt,, and G. Vestris. 1991. In vitro susceptibilities of Coxiella burnetii, Rickettsia rickettsii, and Rickettsia conorii to the fluoroquinolone sparfloxacin. Antimicrob. Agents Chemother. 35:8891.
70. Raoult, D.,, P. Houpikian,, H. Tissot Dupont,, J. M. Riss,, J . Arditi-Djiane,, and P. Brouqui. 1999. Treatment of Q fever endocarditis: comparison of 2 regimens containing doxycycline and ofloxacin or hydroxychloroquine. Arch. Intern. Med. 159:167173.
71. Raoult, D.,, M. R. Yeaman,, and and O. G. Baca. 1989. Susceptibiltiy of Rickettsia and Coxiella burnetii to quinolones. Antimicrob. Agents Chemother. 35:20707077.
72. Raoult, D.,, H. Torres,, and M. Drancourt. 1991. Shell-vial assay:evaluation of a new technique for determining antibiotic susceptibility, tested in 13 isolates of Coxiella burnetii. Antimicrob. Agents Chemother. 35:20702077.
73. Reyes, M. P.,, and A. M. Lerner. 1983. Current problems in the treatment of infective endocarditis due to Pseudomonas aeruginosa. Rev. Infect. Dis. 5:314321.
74. Roman, M.J.,, P. D. Coriz,, and O. G. Baca. 1986. A proposed model to explainpersistent infection of host cells with Coxiella burnetii. J. Gen. Microbiol. 132(Pt. 5):14151422.
75. Rouse, M. S.,, R. M. Wilcox,, N. K. Henry,, J. M. Steckelberg,, and W. R. Wilson. 1990. Ciprofloxacin therapy of experimental endocarditis caused by methicillin-resistant Staphylococcus epidermidis. Antimicrob. Agents Chemother. 34:273276.
76. Samuel, J. E.,, M. E. Frazier,, and L. P. Mallavia. 1985. Correlation of plasmid type and disease caused by Coxiella burnetii. Infect. Immun. 49:775779.
77. Sanders, C. C.,, and W. E. Sanders, Jr. 1983. Emergence of resistance during therapy with the newer beta-lactam antibiotics: role of inducible beta-lactamases and implications for the future. Rev. Infect. Dis. 5:639648.
78. Sanders, C. C.,, W. E. Sanders, Jr.,, and R. V. Goering. 1987. Overview of preclinical studies with ciprofloxacin. Am. J. Med. 82:211.
79. Sanders, C. C.,, W. E. Sanders, Jr.,, R. V. Goering,, and V. Werner. 1984. Selection of multiple antibiotic resistance by quinolones, beta-lactams, and aminoglycosides with special reference to cross-resistance between unrelated drug classes. Antimicrob. Agents Chemother. 26:797801.
80. Schaefler, S. 1989. Methicillin-resistant strains of Staphylococcus aureus resistant to quinolones. J. Clin. Microbiol. 27:335336.
81. Sexton, D. J.,, M. J. Tenenbaum,, W. R. Wilson,, J. M. Steckelberg,, A. D. Tice,, D. Gilbert,, W. Dismukes,, R. H. Drew,, and D. T. Durack. 1998. Ceftriaxone once daily for four weeks compared with ceftriaxone plus gentamicin once daily for two weeks for treatment of endocarditis due to penicillin-susceptible streptococci. Endocarditis Treatment Consortium Group. Clin. Infect. Dis. 27:14701474.
82. Shekar, R.,, T. W. Rice,, C. H. Zierdt,, and C. A. Kallick. 1985. Outbreak of endocarditis caused by Pseudomonas aeruginosa serotype O1l among pentazocine and tripelennamine abusers in Chicago. J. Infect. Dis. 151:203208.
83. Spelman, D. W. 1982. Q fever: a study of 111 consecutive cases. Med. J. Aust. 1:547, 548, 551, 553.
84. Spyridaki, I.,, A. Psaroulaki,, A. Aransay,, E. Scoulica,, and Y. Tselentis. 2000. Diagnosis of quinolone-resistant Coxiella burnetii by PCR-RFLP. J. Clin. Lab. Anal. 14:5963.
85. Strunk, R. W.,, J . C. Gratz,, R. Maserati,, and W. M. Scheld. 1985. Comparison of ciprofloxacin with azlocillin plus tobramycin in the therapy of experimental Pseudomonas aeruginosa endocarditis. Antimicrob. Agents Chemother. 28:428432.
86. Sullam, P. M.,, M. G. Tauber,, C. J. Hackbarth,, H. F. Chambers,, K. G. Scott,, and M. A. Sande. 1985. Pefloxacin therapy for experimental endocarditis caused by methicillinsusceptible or methicillin-resistant strains of Staphylococcus aureus. Antimicrob. Agents Chemother. 27:685687.
87. Thrupp, L.D.Susceptibiltiy testing of antibiotics in liquidmedia, p. 73113. In V. Lorian (ed.), Antibiotics in Laboratory Medicine. The Williams & Wilkins Co., Baltimore, Md.
88. Trucksis, M.,, D. C. Hooper,, and J. S. Wolfson. 1991. Emerging resistance to fluoroquinolones in staphylococci: an alert. Ann. Intern. Med. 114:424426.
89. Uzun, O.,, H. E. Akalin,, S. Unal,, M. Demircin,, A. C. Yorgancioglu,, and B. Ugurlu. 1992. Long-term oral ciprofloxacin in the treatment of prosthetic valve endocarditis due to Pseudomonas aeruginosa. Scand. J. Infect. Dis. 24:797800.
90. Vazquez, J.,, M. B. Perri,, L. A. Thai,, S. A. Donabedian,, and M. J. Zervos. 1993. Sparfloxacin and clinafloxacin alone or in combination with gentamicin for therapy of experimental ampicillin-resistant enterococcal endocarditis in rabbits. J. Antimicrob. Chemother. 32:715721.
91. Whitman, M.S.,, P. G. Pitsakis,, A. Zausner,, L. L. Livornese,, A. J . Osborne,, C. C. Johnson,, and M. E. Levison. 1993. Antibiotic treatment of experimental endocarditis due to vancomycin- and ampicillin-resistant Enterococcus faecium. Antimicrob. Agents Chemother. 37:20692073.
92. Xiong, Y. Q.,, G. Potel,, J . Caillon,, G. Stephant,, F. Jehl,, D. Bugnon,, P. Le Conte,, D. Baron,, and H. Drugeon. 1995. Comparative efficacies of ciprofloxacin and pefloxacin alone or in combination with fosfomycin in experimental endocarditis induced by multidrug-susceptible and -resistant Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 39:496499.
93. Yeaman, M. R.,, and O. G. Baca. 1991. Mechanisms that may account for differential antibiotic susceptibilities among Coxiella burnetii isolates. Antimicrob. Agents Chemother. 35:948954.
94. Yeaman, M. R.,, and O. G. Baca. 1990. Unexpected antibiotic susceptibility of a chronic isolate of Coxiella burnetii. Ann. N. Y. Acad. Sci. 590:297305.
95. Yeaman, M. R.,, L. A. Mitscher,, and O. G. Baca. 1987. In vitro susceptibility of Coxiella burnetii to antibiotics, including several quinolones. Antimicrob. Agents Chemother. 31:10791084.
96. Yeaman, M. R.,, M. J . Roman,, and O. G. Baca. 1989. Antibiotic susceptibilities of two Coxiella burnetii isolates implicated in distinct clinical syndromes. Antimicrob. Agents Chemother. 33:10521057.
97. Yeaman, M.R.,, and O. G. Baca,. 1990. Antibiotic susceptibilityof Coxiella burnetii, p. 213223. In T. J. Marrie (ed.), Q fever, vol. 1. The Disease. CRC Press, Inc., Boca Raton, Fla.
98. Yebra, M.,, J. Ortigosa,, F. Albarran,, and M. G. Crespo. 1990. Ciprofloxacin in a case of Q fever endocarditis. N. Engl. J. Med. 323:614.
99. Zaman, M. M.,, D. Landman,, S. Burney,, and J. M. Quale. 1996. Treatment of experimental endocarditis due to multidrug- resistant Enterococcus faecium with clinafloxacin and penicillin. J. Antimicrob. Chemother. 37:127132.
100. Zeiler, H. J. 1985. Evaluation of the in vitro bactericidal action of ciprofloxacin on cells of Escherichia coli in the logarithmic and stationary phases of growth. Antimicrob. Agents Chemother. 28:524527.

Tables

Generic image for table
Table 1

Summary of in vivo activity of fluoroquinolones in animal endocarditis models

Citation: Le T, Yeaman M, Bayer A. 2003. Treatment of Experimental and Human Bacterial Endocarditis with Quinolone Antimicrobial Agents, p 259-273. In Hooper D, Rubinstein E (ed), Quinolone Antimicrobial Agents, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555817817.ch16
Generic image for table
Table 2

Summary of activity of fluoroquinolones in human bacterial endocarditis

Citation: Le T, Yeaman M, Bayer A. 2003. Treatment of Experimental and Human Bacterial Endocarditis with Quinolone Antimicrobial Agents, p 259-273. In Hooper D, Rubinstein E (ed), Quinolone Antimicrobial Agents, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555817817.ch16

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error